New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
10:48 EDTAMRNAmarin shares slightly lower after FDA updates Orange Book
Amarin shares are down 10c, or 1.15%, to $8.57 after an update in the FDA's Orange Book regarding the company's drug Vascepa said, "There is no unexpired exclusivity for this product." The FDA posting noted that the Orange Book Data was updated through January, 2013 and that patent and generic drug product data was last updated on February 19. Reference Link
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:17 EDTAMRNAmarin announces two presentations on EPA dyslipidemia studies
Amarin announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings. The EPA+DHA to EPA-only switch study investigated the effect of EPA-only omega-3 therapy compared to EPA+DHA therapy on multiple patient lipid parameters. Results of this case series showed a reduction in both triglyceride and low-density lipoprotein cholesterol levels with EPA-only therapy in most of these high-risk statin-treated patients. The ANCHOR sub-analysis is an encore presentation which examined the effect of EPA on high-risk statin-treated patients with persistently high triglyceride levels, showing that icosapent ethyl increased EPA in plasma and red blood cells in a linear, dose-dependent fashion consistent with its triglyceride-lowering effect.
July 24, 2015
16:38 EDTAMRNAmarin files to sell 38.9M series A preference shares in form of ADS for holders
Subscribe for More Information
16:34 EDTAMRNAmarin files to sell 3.89M ordinary shares in form of ADS for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use